Furthermore, a significant correlation exists between MET amplification and the activation of other driver genes, such as EGFR and KRAS, implying that MET amplification may represent one of the mechanisms contributing to acquired resistance in NSCLC characterized by EGFR mutations (Wang et al., 2019). Here, MET is linked to non-small cell lung carcinoma.